UpJohn US 2 LLC

Strides Pharma Secures USFDA Approval for Celecoxib Capsules, Targeting $116M Market

- Strides Pharma Science's Singapore subsidiary has received USFDA approval for Celecoxib Capsules in 100 mg, 200 mg, and 400 mg dosages, strengthening its anti-inflammatory portfolio. - The approved product is bioequivalent to Celebrex Capsules and will be manufactured at the company's Puducherry facility in India, addressing a market worth approximately $116 million. - Celecoxib, a selective COX-2 inhibitor, is widely prescribed for managing pain and inflammation associated with osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea.